Melatonin and Migraine in Children: Can a Supplement Replace Preventive Medication?

Migraine in children is often dismissed as an ordinary headache, but it's actually a distinct neurological condition that can knock a child out of school, play, and sleep for hours at a time, and in more severe cases recur several times a month for years. In children, nausea, vomiting, and sensitivity to light and sound accompany it more often than in adults, and the attacks themselves tend to be shorter, which sometimes makes diagnosis and differentiation from other causes of headache harder.

When attacks are frequent or significantly disrupt functioning, doctors consider preventive treatment — a medication taken daily meant to reduce the frequency and severity of future attacks, as opposed to acute medications taken during an attack itself. Classic preventive drugs used in children, such as amitriptyline or topiramate, can be effective, but they also carry side effects — drowsiness, weight gain, difficulty concentrating — which are a particularly important factor for parents and doctors when choosing therapy for a developing child.

In this context, melatonin, the hormone that regulates the circadian rhythm and which we cover in more depth in our entry on melatonin, seems like a tempting alternative — it's available without a prescription, has an established reputation as a relatively mild agent, and is associated more with safe sleep support than with a neurological drug. The question is whether that reputation holds up under rigorously designed clinical trials in children, rather than resting on extrapolation from adult studies or informal observations.

The hypothesis about melatonin's role in migraine didn't come out of nowhere. Migraine has a strong link to the circadian rhythm — in many patients attacks occur at characteristic times of day, and sleep disturbances are simultaneously a common trigger for an attack and a common consequence of the disease itself. Melatonin, as the main hormone regulating the biological clock, also has anti-inflammatory and antioxidant properties that could theoretically influence the mechanisms underlying migraine, independent of its effect on sleep alone.

In adults, earlier studies had suggested that melatonin taken every evening might reduce migraine attack frequency — and it was exactly these results that directly inspired the research team at the University of California, San Francisco (UCSF) to test whether a similar effect could be reproduced in a carefully designed trial in children and adolescents, where this kind of evidence had previously been lacking.

Before the UCSF trial, an Iranian team from Shahid Sadoughi University of Medical Sciences in Yazd published a smaller, single-blind randomized trial that directly compared melatonin with amitriptyline — one of the standard preventive drugs used in pediatric migraine. The trial enrolled 80 children aged 5-15, who received amitriptyline (1 mg/kg) or melatonin (0.3 mg/kg) for three months.

A good response to treatment was seen in 82.5% of children on amitriptyline versus 62.5% on melatonin — a statistically significant difference favoring amitriptyline (p=0.04). Both substances significantly reduced headache severity, duration, and the PedMIDAS score, which assesses how much migraine disrupts a child's daily functioning, but amitriptyline's effect was more pronounced across nearly every dimension. At the same time, melatonin proved clearly better tolerated: daytime sleepiness was reported by 7.5% of children on melatonin versus a 22.5% combined adverse event rate in the amitriptyline group (sleepiness, constipation, fatigue), a statistically significant difference (p=0.04).

One of the more interesting elements of the UCSF trial's methodology was the 8-week lead-in period, during which all participants — before actual randomization — received placebo, knowing they might, but wouldn't necessarily, later be assigned to real treatment. The purpose of such a design is to screen out people in whom clinical attention itself, keeping a headache diary, and regular contact with the research team already produce improvement unrelated to any active substance — a well-known phenomenon in pediatric headache research.

In the UCSF trial, as many as 21% of participants failed to meet the criteria for randomization after this lead-in period, mainly because their headache-day count dropped below the inclusion threshold even before receiving any active treatment. This shows how strong the effect of mere observation can be, and how easily uncontrolled parental reports of a "miraculous" effect of any supplement on a child's migraine might reflect the disease's natural variability rather than a real pharmacological effect.

It's also worth remembering that "natural" doesn't mean "free of side effects or interactions" — melatonin affects the circadian rhythm and in some children can cause excessive daytime sleepiness, paradoxically worsened morning headaches, or mood changes, especially with uncontrolled dosing without medical consultation.

It's rare to find such an honest example of how difficult research into pediatric migraine can be: the UCSF team designed a trial to the highest methodological standards, and yet practical recruitment difficulties prevented a clear-cut answer. This isn't a failure of science but exactly what science is supposed to be — admitting uncertainty instead of stretching conclusions from insufficient data.